<p>"At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data," said Wendy Painter, chief medical officer of the US firm, Ridgeback Biotherapeutics.</p><p>In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, including a pill-based one called molnupiravir, which it has developed with Ridgeback Biotherapeutics.</p><p>This drug caused a significant drop in patients' viral load after five days of treatment with it, Merck said at a meeting with infectious disease experts.</p><p>This Phase 2a test -- drug trials have three stages before a product can be approved -- was carried out among 202 non-hospitalized people with symptoms of Covid-19.</p><p>There was no alert in terms of safety, and of four serious adverse events that were reported, none were considered to be related to taking this drug, Ridgeback said.</p><p>Anti-viral oral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) are sometimes prescribed for seasonal flu but researchers have yet to come up with something similar to fight the coronavirus.</p><p>The findings of this study -- a quicker decrease in viral load among individuals with early-stage Covid-19 who are treated with molnupiravir -- are promising, said William Fischer, lead investigator of the study and a professor of medicine at the University of North Carolina.</p><p>"If supported by additional studies, (they) could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally," Fischer added.</p><p>Merck is also working on another oral Covid treatment called MK-711.</p><p>Preliminary results from clinical trials with it show a more than 50 percent reduction in risk of death or respiratory trouble in patients hospitalized with moderate to severe Covid-19, the company said in January.</p>
CONTINUE READING
Show less